SOMERSET, N.J. (PRWEB) February 20, 2020
Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced it will host a one day workshop to demonstrate the benefits of an integrated biologics development strategy, titled, “Achieving Integrated Biologics Development: Challenges and How to Tackle Them”. The event will be held at the Royal Society of Chemistry’s headquarters in London, U.K., on March 12, 2020.
Held in partnership with One Nucleus, the Cambridge-London life science membership organization, the workshop will focus on the development of sterile and biologics products, and will explore how a comprehensive solution from development, clinical and commercial-scale manufacturing and finished product supply has the potential to provide higher quality, and improved yields of biopharmaceuticals as well as reducing a project’s cost and timeline.
Alongside Catalent experts at the event will be speakers from across the biopharmaceutical industry, including Sartorius, Ypsomed and Unchained Labs, and presentations will include discussions on how the power of big data, combined with optimized cell line engineering and advanced screening techniques, can reduce biologics development timelines from months to weeks.
For more information and to register for the event, visit https://biologics.catalent.com/events/achieving-integrated-biologics-development.
To arrange a meeting with any of the attending Catalent experts at the event, contact Richard Kerns at NEPR - firstname.lastname@example.org.
About Catalent Biologics
Catalent Biologics is a global leader in development, manufacturing and analytical services for new biological entities, cell and gene therapies, biosimilars, sterile injectables, and antibody-drug conjugates. With over 20 years of proven expertise, Catalent Biologics has worked with 600+ mAbs and 80+ proteins, produced 13 biopharmaceutical drugs using GPEx® cell line development technology, and launched 25+ commercial products. Catalent has recently acquired MaSTherCell, a technology-focused cell therapy development and manufacturing partner with expertise in autologous and allogeneic cell therapy that complements Catalent’s industry-leading expertise and commercial success in gene therapy development, manufacturing and adeno-associated virus (AAV) vector production. Together, Paragon Gene Therapy and MaSTherCell have produced over 100 GMP batches across 60+ clinical and commercial programs. For more information on Catalent Biologics, visit http://www.catalent.com/biologics
Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs over 13,000 people, including over 2,400 scientists and technicians, at more than 35 facilities, and in fiscal year 2019 generated over $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com
More products. Better treatments. Reliably supplied.™